Zhao Wen, Wen Jian-Xun, Niu Yan, Yan Li, Wang Mei-Ying, Jiao Wei, Wang Ya-Fei, Gao Wen-Hui, Yang Dan-Ni, Zheng Wen-Qi, Hu Zhi-De
Center for Clinical Epidemiology Research, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Department of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Transl Lung Cancer Res. 2025 Apr 30;14(4):1138-1148. doi: 10.21037/tlcr-2024-1205. Epub 2025 Apr 16.
Biomarkers in pleural fluid are the potential auxiliary diagnostic markers for malignant pleural effusion (MPE). Exosomal microRNAs (miRNAs) represent novel diagnostic markers for various diseases. The diagnostic performance of exosomal miRNAs for MPE remains unclear. Therefore, we examined the exosomal miRNAs profiles of both MPE and benign pleural effusion (BPE), aiming to study diagnostic performance of exosomal miRNAs for MPE.
We used next-generation sequencing (NGS) technology to analyze the pleural fluid exosomal miRNA profile in five MPE and 15 BPE cases. We analyzed the differentially expressed exosomal miRNAs by reverse transcription polymerase chain reaction (RT-PCR), with cel-miR-39 or snRNA U6 as internal references. We assessed the diagnostic accuracy of exosomal miRNA for MPE with a receiver operating characteristic (ROC) curve. We also analyzed whether exosomal miRNA could improve the diagnostic performance of pleural carcinoembryonic antigen (CEA).
Fifty-eight miRNAs were up-regulated, and 35 miRNAs were down-regulated in MPE. We selected exosomal miR-182-5p for further study and analyzed miR-182-5p in 153 patients with undiagnosed pleural effusion. Exosomal miR-182-5p was undetectable in 32 participants. In the remaining participants with 49 MPE and 72 BPE cases, we found that the areas under the curve (AUCs) and their 95% confidence intervals (95% CIs) for exosomal miR-182-5p were 0.78 (95% CI: 0.69-0.86) when using cel-miR-39 as an internal reference, and 0.80 (95% CI: 0.73-0.88) when using snRNA U6. The combination of exosomal miR-182-5p and CEA can slightly improve the diagnostic accuracy of MPE, with an AUC of 0.91 (95% CI: 0.85-0.97).
Pleural miR-182-5p can assist in the diagnosis of MPE. Its diagnostic performance is slightly affected by internal reference.
胸腔积液中的生物标志物是恶性胸腔积液(MPE)潜在的辅助诊断标志物。外泌体微小RNA(miRNA)是多种疾病的新型诊断标志物。外泌体miRNA对MPE的诊断性能尚不清楚。因此,我们检测了MPE和良性胸腔积液(BPE)的外泌体miRNA谱,旨在研究外泌体miRNA对MPE的诊断性能。
我们使用下一代测序(NGS)技术分析了5例MPE和15例BPE病例的胸腔积液外泌体miRNA谱。我们以cel-miR-39或小核RNA U6为内参,通过逆转录聚合酶链反应(RT-PCR)分析差异表达的外泌体miRNA。我们用受试者工作特征(ROC)曲线评估外泌体miRNA对MPE的诊断准确性。我们还分析了外泌体miRNA是否能提高胸腔癌胚抗原(CEA)的诊断性能。
MPE中有58个miRNA上调,35个miRNA下调。我们选择外泌体miR-182-5p进行进一步研究,并在153例未确诊胸腔积液患者中分析miR-182-5p。32名参与者中未检测到外泌体miR-182-5p。在其余49例MPE和72例BPE病例的参与者中,我们发现以cel-miR-39为内参时,外泌体miR-182-5p的曲线下面积(AUC)及其95%置信区间(95%CI)为0.78(95%CI:0.69-0.86),以小核RNA U6为内参时为0.80(95%CI:0.73-0.88)。外泌体miR-182-5p和CEA联合使用可略微提高MPE的诊断准确性,AUC为0.91(95%CI:0.85-0.97)。
胸腔miR-182-5p可辅助MPE的诊断。其诊断性能受内参的影响较小。